{
    "nct_id": "NCT06517888",
    "official_title": "A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals with Unilateral Vestibular Schwannoma",
    "inclusion_criteria": "Criteria for Inclusion:\n\n1. Presence of unilateral, progressive vestibular schwannoma.\n2. Vestibular schwannoma larger than 2 mm.\n3. Profound hearing loss, defined by pure-tone audiometry thresholds or word recognition score, in the affected ear.\n4. Able and willing to comply with all trial requirements, including willingness to participate in a separate long term follow-up study after completion of this trial.\n\nCriteria for Exclusion:\n\n1. Prior diagnosis of NF2 and/or bilateral vestibular schwannoma.\n2. Prior surgery or radiation therapy for vestibular schwannoma.\n3. Clinical history consistent with endolymphatic hydrops (documented fluctuating sensorineural hearing loss and/or episodic vertigo) in the affected ear.\n4. Profound hearing loss, defined by pure-tone audiometry thresholds or word recognition score, in the unaffected ear.\n5. Prior participation in a clinical trial with an investigational drug within six months prior to administration (Day 0), or any prior participation in a gene therapy clinical trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}